[{"quiz_id": "ABMS20260101_claude-opus-4-5-20251101_p04", "question_id": "ABMS20260101_claude-opus-4-5-20251101_p04-001", "question": "An 82-year-old woman with moderate Alzheimer's dementia (MMSE 18) living in assisted living is hospitalized for community-acquired pneumonia. On hospital day 2, she becomes acutely agitated with visual hallucinations. Her medications include donepezil, memantine, and lisinopril. She is started on haloperidol 0.5 mg for agitation. On day 3, she develops temperature 39.2°C, severe muscle rigidity, diaphoresis, and altered consciousness. Laboratory studies show CK 8,500 U/L and WBC 14,000/μL. Which mechanism best explains this presentation?", "options": ["Anticholinergic toxicity from haloperidol-donepezil interaction", "Dopamine receptor blockade causing neuroleptic malignant syndrome", "Serotonin syndrome from memantine-haloperidol interaction", "Malignant hyperthermia triggered by infection", "Central fever from hypothalamic involvement by infection"], "answer": "B", "answer_index": 1, "explanation": "This patient has developed neuroleptic malignant syndrome (NMS) following haloperidol administration, characterized by the classic tetrad of hyperthermia, severe rigidity, altered mental status, and autonomic instability with elevated CK. Elderly patients with dementia are at increased risk for NMS. The mechanism is dopamine D2 receptor blockade in the hypothalamus and nigrostriatal pathways. While donepezil increases acetylcholine (potentially worsening extrapyramidal symptoms), the presentation is classic for NMS rather than anticholinergic toxicity. Memantine is an NMDA antagonist with minimal serotonergic activity, making serotonin syndrome unlikely.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Geriatrics", "abms_specialty": "Geriatrics", "abms_source": "target_topic", "source_label_raw": "Geriatrics", "source_quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "source_question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-009", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/claude-opus-4-5-20251101/20251218T014545383Z_claude-opus-4-5-20251101_seed130", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251218T014545383Z_claude-opus-4-5-20251101_seed130.jsonl", "pred": "B", "model_outputs": "The patient is on haloperidol (a typical antipsychotic) and develops acute fever, severe rigidity, altered consciousness, diaphoresis, and markedly elevated CK, consistent with neuroleptic malignant syndrome (NMS). NMS is caused by dopamine receptor blockade in the basal ganglia and hypothalamus.  \n\nWhile infection and other causes are possible, the presentation and timing after starting haloperidol point most specifically to NMS.  \n\nThe answer is (B)"}, {"quiz_id": "ABMS20260101_claude-opus-4-5-20251101_p04", "question_id": "ABMS20260101_claude-opus-4-5-20251101_p04-002", "question": "A 6-year-old boy presents with progressive gait instability, frequent falls, and difficulty climbing stairs over the past year. Physical examination reveals calf pseudohypertrophy, positive Gowers' sign, and proximal muscle weakness. Creatine kinase is 15,400 U/L. Genetic testing confirms a deletion in the dystrophin gene consistent with Duchenne muscular dystrophy. Echocardiogram shows normal left ventricular function. The family asks about disease-modifying therapy. The child weighs 22 kg. Which of the following treatments is most likely to slow disease progression in this patient?", "options": ["Deflazacort 0.9 mg/kg/day", "Eteplirsen 30 mg/kg weekly intravenously", "Ataluren 40 mg/kg/day in three divided doses", "Golodirsen 30 mg/kg weekly intravenously", "Idebenone 900 mg daily"], "answer": "A", "answer_index": 0, "explanation": "Deflazacort (and prednisone) are the only treatments with robust evidence demonstrating slowed disease progression in Duchenne muscular dystrophy, including prolonged ambulation, preserved pulmonary function, and delayed cardiomyopathy. Deflazacort may have a slightly better side effect profile than prednisone. Exon-skipping therapies (eteplirsen, golodirsen) are only applicable to specific mutations amenable to exon skipping and have shown only modest dystrophin production without clear clinical benefit. Ataluren is for nonsense mutations only. Idebenone showed no benefit in the DELOS trial for patients on corticosteroids.", "generator_model": "claude-opus-4-5-20251101", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "abms_specialty": "Pediatrics", "abms_source": "target_topic", "source_label_raw": "Pediatrics", "source_quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed128", "source_question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed128-011", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/claude-opus-4-5-20251101/20251218T014545383Z_claude-opus-4-5-20251101_seed128", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251218T014545383Z_claude-opus-4-5-20251101_seed128.jsonl", "pred": "A", "model_outputs": "The patient has a confirmed dystrophin gene deletion consistent with Duchenne muscular dystrophy.  \nAmong the options:  \n\n- **A. Deflazacort** — a corticosteroid shown to slow disease progression in DMD regardless of mutation type; standard of care for ambulatory patients.  \n- **B. Eteplirsen** — indicated only for patients with a confirmed mutation amenable to exon 51 skipping (about 13% of cases).  \n- **C. Ataluren** — indicated only for nonsense (stop codon) mutations, not deletions.  \n- **D. Golodirsen** — indicated only for mutations amenable to exon 53 skipping.  \n- **E. Idebenone** — not FDA-approved for DMD; used in some countries for cardiomyopathy in DMD but not for slowing overall disease progression in a patient with normal cardiac function.  \n\nSince the question does not specify an exon-skipping amenable deletion, the only therapy among these that is broadly applicable and disease-modifying for DMD is corticosteroids. Deflazacort is dosed at approximately 0.9 mg/kg/day.  \n\nThe answer is (A)"}, {"quiz_id": "ABMS20260101_claude-opus-4-5-20251101_p04", "question_id": "ABMS20260101_claude-opus-4-5-20251101_p04-003", "question": "A 24-year-old man is brought to the emergency department after being rescued from a house fire. He has extensive full-thickness burns covering an estimated 65% total body surface area. He is intubated in the field for airway protection. Initial resuscitation is begun with lactated Ringer's solution using the Parkland formula. Six hours into resuscitation, he has received 14 liters of crystalloid. Vital signs: BP 88/52 mmHg, HR 132 bpm. Urine output over the past 2 hours is 15 mL total. Bladder pressure is 32 mmHg. Peak airway pressures have increased from 28 to 48 cmH2O. Which of the following is the most appropriate next step?", "options": ["Increase crystalloid infusion rate by 50%", "Add albumin 5% to resuscitation fluids", "Perform bilateral chest escharotomies", "Perform decompressive laparotomy", "Perform bedside abdominal escharotomy"], "answer": "E", "answer_index": 4, "explanation": "This patient has developed abdominal compartment syndrome (ACS) in the setting of massive burn resuscitation, evidenced by oliguria, hypotension, elevated bladder pressure (>20 mmHg with organ dysfunction), and elevated airway pressures. In burn patients with circumferential or near-circumferential truncal burns, abdominal escharotomy can effectively decompress the abdomen without the morbidity of laparotomy. This should be attempted before decompressive laparotomy. Increasing crystalloid will worsen edema and compartment pressures. Chest escharotomies address thoracic restriction but not abdominal compartment syndrome. Albumin may reduce total fluid requirements but won't acutely address ACS.", "generator_model": "claude-opus-4-5-20251101", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Emergency Medicine", "abms_specialty": "Emergency Medicine", "abms_source": "target_topic", "source_label_raw": "Emergency Medicine", "source_quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed128", "source_question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed128-012", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/claude-opus-4-5-20251101/20251218T014545383Z_claude-opus-4-5-20251101_seed128", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251218T014545383Z_claude-opus-4-5-20251101_seed128.jsonl", "pred": "E", "model_outputs": "The patient has signs of abdominal compartment syndrome (bladder pressure 32 mmHg, oliguria, increased peak airway pressures, hypotension) in the setting of massive fluid resuscitation for major burns.  \nAbdominal compartment syndrome is a surgical emergency requiring decompression. In burn patients with circumferential abdominal eschars, an abdominal escharotomy may relieve external restriction and potentially lower intra-abdominal pressure. If compartment syndrome persists despite escharotomy, decompressive laparotomy may be needed, but escharotomy is the less invasive first step in this scenario.  \n\nGiven the bladder pressure >30 mmHg with organ dysfunction, and the fact that he has full-thickness burns over a large TBSA, **bedside abdominal escharotomy** is the appropriate initial intervention.  \n\nThe answer is E"}, {"quiz_id": "ABMS20260101_claude-opus-4-5-20251101_p04", "question_id": "ABMS20260101_claude-opus-4-5-20251101_p04-004", "question": "A 28-year-old woman at 32 weeks gestation presents with severe headache, visual changes, and right upper quadrant pain. Blood pressure is 178/112 mmHg. Laboratory studies show platelets 62,000/μL, AST 342 U/L, ALT 298 U/L, LDH 890 U/L, creatinine 1.8 mg/dL, and peripheral smear with schistocytes. Urinalysis shows 3+ protein. She receives magnesium sulfate and labetalol. Despite delivery 6 hours later, her platelet count drops to 28,000/μL and creatinine rises to 3.2 mg/dL over the next 48 hours. ADAMTS13 activity returns at 68%. Which of the following is the most appropriate next step in management?", "options": ["Initiate therapeutic plasma exchange", "Administer eculizumab", "Begin rituximab infusion", "Transfuse platelets to maintain count above 50,000/μL", "Continue supportive care with expectant management"], "answer": "B", "answer_index": 1, "explanation": "This patient has pregnancy-associated atypical hemolytic uremic syndrome (aHUS), evidenced by persistent/worsening microangiopathic hemolytic anemia and renal failure after delivery with ADAMTS13 activity >10% (ruling out TTP). Complement-mediated aHUS can be triggered by pregnancy and does not resolve with delivery alone. Eculizumab, a C5 complement inhibitor, is the treatment of choice for aHUS. Plasma exchange is first-line for TTP (ADAMTS13 <10%) but less effective in aHUS. Rituximab targets B cells and is used for autoimmune TTP. Platelet transfusion is relatively contraindicated in TMA. Expectant management risks progressive renal failure.", "generator_model": "claude-opus-4-5-20251101", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Obstetrics and Gynecology", "abms_specialty": "Obstetrics and Gynecology", "abms_source": "topics_mapped", "source_label_raw": "obstetrics", "source_quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125", "source_question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125-007", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/claude-opus-4-5-20251101/20251129T135352000Z_claude-opus-4-5-20251101_seed125", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251129T135352000Z_claude-opus-4-5-20251101_seed125.jsonl", "pred": "E", "model_outputs": "The patient has findings consistent with severe preeclampsia with HELLP syndrome (hemolysis, elevated liver enzymes, low platelets) with progression to acute kidney injury. The key point is that ADAMTS13 activity is 68% (normal >67%), which effectively rules out thrombotic thrombocytopenic purpura (TTP), where activity is typically <10%.  \n\nThe appropriate management after delivery, absent evidence of TTP or atypical hemolytic uremic syndrome (which eculizumab would treat), is supportive care with monitoring, as HELLP usually improves postpartum.  \n\nPlatelet transfusion is generally avoided unless there is active bleeding or need for invasive procedure, as it can worsen endothelial injury. Plasma exchange is not indicated without TTP.  \n\nGiven the timeline and normal ADAMTS13, expectant management with continued supportive care is most appropriate.  \n\nThe answer is E"}, {"quiz_id": "ABMS20260101_claude-opus-4-5-20251101_p04", "question_id": "ABMS20260101_claude-opus-4-5-20251101_p04-005", "question": "A 72-year-old woman with severe aortic stenosis (valve area 0.6 cm², mean gradient 58 mmHg) and preserved ejection fraction is scheduled for transcatheter aortic valve replacement. During the procedure under general anesthesia, rapid ventricular pacing at 180 bpm is initiated for valve deployment. Immediately after pacing is terminated, the arterial line shows a pressure of 45/30 mmHg with a heart rate of 42 bpm. TEE reveals severe paravalvular regurgitation and a pericardial effusion of 1.8 cm with right atrial collapse. Which of the following is the most appropriate immediate intervention?", "options": ["Initiate cardiopulmonary bypass via femoral cannulation", "Administer atropine 1 mg and epinephrine 100 mcg", "Perform emergent pericardiocentesis via subxiphoid approach", "Deploy a second transcatheter valve within the first valve", "Initiate peripheral venoarterial extracorporeal membrane oxygenation"], "answer": "C", "answer_index": 2, "explanation": "The clinical picture demonstrates cardiac tamponade (pericardial effusion with right atrial collapse and profound hypotension) likely from annular rupture or wire perforation during TAVR. Emergent pericardiocentesis is the immediate life-saving intervention to relieve tamponade physiology. While VA-ECMO or cardiopulmonary bypass may ultimately be needed, pericardiocentesis can be performed immediately and may stabilize the patient. Pharmacologic support alone will not address the mechanical problem. Deploying a second valve does not address the tamponade and may worsen annular injury.", "generator_model": "claude-opus-4-5-20251101", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Anesthesiology", "abms_specialty": "Anesthesiology", "abms_source": "target_topic", "source_label_raw": "Anesthesiology", "source_quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed128", "source_question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed128-004", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/claude-opus-4-5-20251101/20251218T014545383Z_claude-opus-4-5-20251101_seed128", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251218T014545383Z_claude-opus-4-5-20251101_seed128.jsonl", "pred": "C", "model_outputs": "The patient has signs of cardiac tamponade (pericardial effusion with right atrial collapse and hypotension) immediately after TAVR, likely due to ventricular perforation.  \nSevere paravalvular leak is also noted, but the immediate life-threatening issue is tamponade, which requires drainage.  \nPericardiocentesis is the fastest way to relieve tamponade in this emergency.  \n\nThe answer is (C)"}, {"quiz_id": "ABMS20260101_claude-opus-4-5-20251101_p04", "question_id": "ABMS20260101_claude-opus-4-5-20251101_p04-006", "question": "A 45-year-old man with bipolar I disorder, currently euthymic on lithium monotherapy (level 0.9 mEq/L), develops new-onset nephrotic syndrome. Renal biopsy reveals minimal change disease. His nephrologist initiates prednisone 60 mg daily. Two weeks later, he presents with decreased need for sleep, pressured speech, grandiosity, and impulsive spending. Lithium level is 0.7 mEq/L. Which of the following is the most appropriate next step in management?", "options": ["Increase lithium dose to achieve level of 1.2 mEq/L", "Add valproic acid 500 mg twice daily", "Add olanzapine 10 mg at bedtime", "Discontinue prednisone and switch to cyclosporine", "Add lamotrigine 25 mg daily with gradual titration"], "answer": "C", "answer_index": 2, "explanation": "This patient has developed corticosteroid-induced mania, a well-recognized complication of high-dose glucocorticoid therapy. The most appropriate acute intervention is adding an atypical antipsychotic such as olanzapine, which has rapid antimanic efficacy and is FDA-approved for acute mania. Increasing lithium is problematic given nephrotic syndrome and potential nephrotoxicity. Valproic acid has hepatic and hematologic concerns with concurrent steroid use. Abruptly discontinuing prednisone could cause nephrotic syndrome relapse and adrenal insufficiency. Lamotrigine has no acute antimanic efficacy and requires slow titration.", "generator_model": "claude-opus-4-5-20251101", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "abms_specialty": "Psychiatry", "abms_source": "target_topic", "source_label_raw": "Psychiatry", "source_quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed128", "source_question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed128-006", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/claude-opus-4-5-20251101/20251218T014545383Z_claude-opus-4-5-20251101_seed128", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251218T014545383Z_claude-opus-4-5-20251101_seed128.jsonl", "pred": "D", "model_outputs": "The patient has bipolar I disorder and is on lithium, currently euthymic. After starting high-dose prednisone for minimal change disease, he develops symptoms of a manic episode despite a therapeutic lithium level (0.7 mEq/L).  \n\nGlucocorticoids like prednisone are known to induce or exacerbate manic symptoms, especially in individuals with bipolar disorder. The most direct approach is to address the trigger—here, the prednisone—while managing the acute mania.  \n\nAmong the options:  \n- **A** – Increasing lithium may not address the steroid-induced mania quickly and risks toxicity if steroids are continued.  \n- **B & E** – Adding mood stabilizers (valproic acid or lamotrigine) may help but doesn’t remove the trigger; lamotrigine is also slow for acute mania.  \n- **C** – Adding an antipsychotic like olanzapine would treat acute mania but ignores the iatrogenic cause.  \n- **D** – Discontinuing prednisone (if possible) and switching to a non-steroid immunosuppressant like cyclosporine addresses the trigger and the underlying nephrotic syndrome, while the acute mania can be managed separately if needed (e.g., with an antipsychotic, though not explicitly stated here).  \n\nGiven the clinical scenario, the most appropriate next step is to remove the offending agent (prednisone) under nephrology guidance while ensuring the nephrotic syndrome is still treated.  \n\n**The answer is D**  \n\nThe answer is D"}, {"quiz_id": "ABMS20260101_claude-opus-4-5-20251101_p04", "question_id": "ABMS20260101_claude-opus-4-5-20251101_p04-007", "question": "A 52-year-old woman with BMI 48 kg/m² undergoes laparoscopic Roux-en-Y gastric bypass. Eighteen months postoperatively, she has lost 95 pounds and presents with recurrent episodes of postprandial confusion, diaphoresis, and tremor that resolve with eating. Symptoms occur 2-3 hours after meals, particularly those high in simple carbohydrates. Fasting glucose is 78 mg/dL. A mixed meal tolerance test demonstrates glucose of 42 mg/dL with insulin of 28 μU/mL and C-peptide of 6.2 ng/mL at 120 minutes. Calcium-stimulated angiography and selective arterial calcium stimulation testing are negative for insulinoma. Which of the following is the most appropriate next step in management?", "options": ["Diazoxide 100 mg three times daily", "Octreotide 100 mcg subcutaneously before meals", "Acarbose 50 mg with meals", "Completion pancreatectomy", "Reversal of gastric bypass to normal anatomy"], "answer": "C", "answer_index": 2, "explanation": "This patient has post-bariatric hypoglycemia (previously called late dumping syndrome or noninsulinoma pancreatogenous hypoglycemia syndrome). The pathophysiology involves exaggerated GLP-1 secretion leading to inappropriate insulin release after rapid glucose absorption. Acarbose, an alpha-glucosidase inhibitor, slows carbohydrate absorption and reduces the glycemic spike that triggers excessive insulin secretion. It is first-line medical therapy. Diazoxide and octreotide are second-line options with more side effects. Pancreatectomy is reserved for refractory cases. Reversal surgery has high morbidity and variable efficacy.", "generator_model": "claude-opus-4-5-20251101", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "General Surgery", "abms_specialty": "General Surgery", "abms_source": "target_topic", "source_label_raw": "General Surgery", "source_quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed128", "source_question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed128-009", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/claude-opus-4-5-20251101/20251218T014545383Z_claude-opus-4-5-20251101_seed128", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251218T014545383Z_claude-opus-4-5-20251101_seed128.jsonl", "pred": "C", "model_outputs": "The patient’s presentation is consistent with postprandial hyperinsulinemic hypoglycemia after gastric bypass (also called post-bariatric hypoglycemia or late dumping syndrome), not insulinoma.  \nThe negative calcium-stimulated angiography and selective arterial calcium stimulation testing rule out insulinoma.  \nIn post-bariatric hypoglycemia, first-line management is dietary modification (low carbohydrate, frequent small meals). If medications are needed, acarbose (an alpha-glucosidase inhibitor) can slow carbohydrate absorption and reduce postprandial insulin surges, making it a reasonable next step before considering more invasive options.  \nDiazoxide and octreotide are used for refractory cases but are not first-line after dietary failure. Completion pancreatectomy or reversal of bypass are last-resort interventions.  \n\nThe answer is C"}, {"quiz_id": "ABMS20260101_claude-opus-4-5-20251101_p04", "question_id": "ABMS20260101_claude-opus-4-5-20251101_p04-008", "question": "A 29-year-old woman presents with acute onset of right-sided weakness and aphasia. CT head is negative for hemorrhage. CT angiography reveals complete occlusion of the left middle cerebral artery M1 segment. CT perfusion shows a small core infarct (8 mL) with large penumbra (95 mL mismatch). Her NIHSS is 18. Time last known well is 2 hours ago. She has a history of antiphospholipid syndrome with prior deep vein thrombosis, currently on warfarin with INR of 3.2. What is the most appropriate acute intervention?", "options": ["Intravenous alteplase followed by mechanical thrombectomy", "Mechanical thrombectomy alone without intravenous thrombolysis", "Intravenous alteplase alone with close monitoring", "Administer 4-factor prothrombin complex concentrate then IV alteplase and thrombectomy", "Anticoagulation reversal with idarucizumab followed by mechanical thrombectomy"], "answer": "B", "answer_index": 1, "explanation": "This patient has a large vessel occlusion with favorable perfusion imaging (small core, large penumbra) within the thrombectomy window. However, her INR of 3.2 is a contraindication to IV alteplase (INR >1.7 is exclusion criterion). Mechanical thrombectomy is not contraindicated by anticoagulation status and should be performed emergently. IV alteplase (A, C) is contraindicated with therapeutic anticoagulation. PCC reversal followed by alteplase (D) delays definitive treatment and alteplase remains relatively contraindicated even after reversal. Idarucizumab (E) reverses dabigatran, not warfarin.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Neurology", "abms_specialty": "Neurology", "abms_source": "topics_mapped", "source_label_raw": "Neurology", "source_quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "source_question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-005", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/claude-opus-4-5-20251101/20251129T135352000Z_claude-opus-4-5-20251101_seed123", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251129T135352000Z_claude-opus-4-5-20251101_seed123.jsonl", "pred": "B", "model_outputs": "The patient has a large vessel occlusion with a small core and large penumbra, making her an excellent candidate for mechanical thrombectomy. However, she is on warfarin with an INR of 3.2, which is above the typical threshold for safe administration of intravenous alteplase (usually INR ≤1.7).  \n\nGiving alteplase with an INR of 3.2 carries a high risk of hemorrhage. Reversal with 4-factor prothrombin complex concentrate (PCC) before alteplase is not standardly recommended in guidelines for enabling thrombolysis, and could still leave other clotting risks from antiphospholipid syndrome unaddressed.  \n\nIdarucizumab is for dabigatran reversal, not warfarin.  \n\nGiven the clear thrombectomy eligibility, the most appropriate approach is to proceed directly to mechanical thrombectomy without intravenous thrombolysis, since the time last known well is only 2 hours and thrombectomy is likely to be rapidly available.  \n\nThe answer is B"}, {"quiz_id": "ABMS20260101_claude-opus-4-5-20251101_p04", "question_id": "ABMS20260101_claude-opus-4-5-20251101_p04-009", "question": "A 38-year-old woman presents with palpitations and near-syncope. ECG shows a regular wide complex tachycardia at 220 bpm with RBBB morphology, northwest axis, and AV dissociation. She is hemodynamically stable with blood pressure 105/70 mmHg. Adenosine 12 mg IV is administered without effect. Procainamide infusion is started, and after 8 minutes (750 mg administered), the rhythm converts to sinus. Post-conversion ECG reveals sinus rhythm with a short PR interval (100 ms), delta waves, and QRS duration of 140 ms with positive delta wave in V1. Which electrophysiologic finding would most strongly support proceeding with catheter ablation rather than medical management?", "options": ["Accessory pathway effective refractory period of 270 ms", "Inducible orthodromic atrioventricular reentrant tachycardia", "Accessory pathway located in the left lateral position", "Shortest pre-excited RR interval during induced atrial fibrillation of 220 ms", "Decremental conduction properties of the accessory pathway"], "answer": "D", "answer_index": 3, "explanation": "This patient has Wolff-Parkinson-White syndrome with documented antidromic AVRT (wide complex tachycardia with AV dissociation, RBBB morphology suggesting left-sided pathway). The most important risk stratification parameter is the shortest pre-excited RR interval (SPERRI) during atrial fibrillation, which reflects the accessory pathway's ability to conduct rapid atrial rates to the ventricle. SPERRI ≤250 ms indicates high-risk pathway capable of conducting AF at rates that could degenerate to ventricular fibrillation, strongly favoring ablation. Accessory pathway ERP (A) is less predictive than SPERRI. Inducible orthodromic AVRT (B) and pathway location (C) don't indicate sudden death risk. Decremental properties (E) actually suggest lower risk.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Cardiovascular", "abms_specialty": "Cardiovascular", "abms_source": "topics_mapped", "source_label_raw": "cardiology", "source_quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "source_question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-010", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/claude-opus-4-5-20251101/20251129T135352000Z_claude-opus-4-5-20251101_seed123", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251129T135352000Z_claude-opus-4-5-20251101_seed123.jsonl", "pred": "D", "model_outputs": "The patient has Wolff-Parkinson-White (WPW) syndrome, as shown by the delta waves and short PR interval after conversion.  \nThe clinical presentation was a wide-complex tachycardia with AV dissociation, consistent with **antidromic AVRT** or possibly atrial fibrillation with pre-excitation, but the given description (regular wide QRS, AV dissociation) is most typical of **ventricular tachycardia** — however, the post-conversion ECG reveals WPW, so the wide-complex tachycardia was likely **antidromic AVRT** or possibly **pre-excited atrial fibrillation** (though it was regular).  \n\nThe key point: in WPW, the main risk factor for sudden cardiac death is rapid conduction over the accessory pathway during atrial fibrillation, which can degenerate into VF.  \nThe **shortest pre-excited RR interval during induced atrial fibrillation** is the standard electrophysiology study metric for risk stratification.  \nA shortest pre-excited RR interval **≤250 ms** (some use ≤220 ms) is considered high risk and supports proceeding with catheter ablation.  \n\nHere, option **D** gives a shortest pre-excited RR interval of 220 ms, which is in the high-risk range and would strongly support ablation over medical management.  \n\nOther options:  \n- A: ERP 270 ms is relatively long, not high risk.  \n- B: Inducible orthodromic AVRT is common but not by itself highest risk for sudden death.  \n- C: Location doesn’t directly indicate high-risk pathway.  \n- E: Decremental conduction is unusual (often seen in PJRT) but not the strongest indicator for ablation in WPW.  \n\nThe answer is D.  \n\nThe answer is D"}, {"quiz_id": "ABMS20260101_claude-opus-4-5-20251101_p04", "question_id": "ABMS20260101_claude-opus-4-5-20251101_p04-010", "question": "A 52-year-old man with type 2 diabetes presents for evaluation of recurrent hypoglycemia occurring 3-4 hours postprandially. He underwent Roux-en-Y gastric bypass 2 years ago with 45 kg weight loss. During a symptomatic episode, laboratory studies show: glucose 38 mg/dL, insulin 45 μU/mL (elevated), C-peptide 8.2 ng/mL (elevated), proinsulin 22 pmol/L (elevated), and negative sulfonylurea screen. Calcium-stimulated angiography localizes insulin secretion to the body and tail of the pancreas. Which of the following is the most appropriate next step in management?", "options": ["Distal pancreatectomy", "Diazoxide therapy", "Octreotide therapy", "Dietary modification with acarbose", "Enucleation of insulinoma"], "answer": "D", "answer_index": 3, "explanation": "This presentation is classic for post-gastric bypass hyperinsulinemic hypoglycemia (nesidioblastosis/non-insulinoma pancreatogenous hypoglycemia syndrome). Unlike insulinoma, this involves diffuse islet cell hyperfunction. First-line management is dietary modification (low glycemic index, frequent small meals) combined with acarbose to slow carbohydrate absorption and blunt the exaggerated incretin response. Distal pancreatectomy is reserved for refractory cases. The diffuse localization on angiography and post-bypass context argue against focal insulinoma requiring enucleation.", "generator_model": "claude-opus-4-5-20251101", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Endocrine", "abms_specialty": "Endocrine", "abms_source": "topics_mapped", "source_label_raw": "endocrinology", "source_quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed127", "source_question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed127-004", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/claude-opus-4-5-20251101/20251129T135352000Z_claude-opus-4-5-20251101_seed127", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251129T135352000Z_claude-opus-4-5-20251101_seed127.jsonl", "pred": "A", "model_outputs": "The patient likely has noninsulinoma pancreatogenous hypoglycemia syndrome (NIPHS) or adult nesidioblastosis, which is a known complication after Roux-en-Y gastric bypass.  \nThe presentation with recurrent postprandial hypoglycemia, elevated insulin and C-peptide, negative sulfonylurea screen, and diffuse rather than focal insulin secretion on calcium angiography all point to diffuse beta-cell hyperplasia rather than a solitary insulinoma.  \n\nDistal pancreatectomy (A) is often the surgical choice for diffuse disease in the body/tail.  \nDiazoxide (B) or octreotide (C) are medical therapies, which may be used but surgery is definitive if medical management fails.  \nAcarbose (D) may help mildly but is not definitive.  \nEnucleation (E) is for solitary insulinoma, not diffuse disease.  \n\nGiven calcium angiography localizing to body/tail, distal pancreatectomy is most appropriate for definitive treatment.  \n\nThe answer is A"}]